Valuation: Arcus Biosciences, Inc.

Market Cap 3.02B 2.69B 2.49B 2.26B 4.25B 285B 4.3B 29.91B 11.74B 150B 11.34B 11.11B 478B P/E 2026 *
-5.39x
P/E 2027 * -5.74x
Enterprise Value 2.58B 2.3B 2.13B 1.93B 3.63B 244B 3.68B 25.56B 10.03B 128B 9.69B 9.49B 408B EV / Sales 2026 *
35.3x
EV / Sales 2027 * 51.7x
Free-Float
71.2%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Arcus Biosciences, Inc.

1 day-19.58%
1 week-15.15%
Current month-26.05%
1 month-24.33%
3 months-32.20%
6 months-16.01%
Current year-19.85%
1 week 18.98
Extreme 18.98
24.7
1 month 18.98
Extreme 18.98
27.9
Current year 18.52
Extreme 18.515
31.74
1 year 16.41
Extreme 16.41
31.74
3 years 6.5
Extreme 6.5
31.74
5 years 6.5
Extreme 6.5
49.1
10 years 6.3
Extreme 6.3
49.1
Manager TitleAgeSince
President 68 30/04/2015
Chief Executive Officer 67 30/04/2015
Director of Finance/CFO 53 31/07/2020
Director TitleAgeSince
Chairman 67 30/11/2017
Director/Board Member 65 17/09/2017
Director/Board Member 72 30/04/2015
Date Insider Type Main position Quantity % Market Cap. Importance
21/08/26 Exercice

Controller/Auditor

8,481 0.0067%
10/07/26 Sell

Founder

-20,067 0.0160%
11/06/26 Free

Director

22,600 0.0180%
Change 5-day change 1-year change 3-year change Capi.($)
-19.58%-15.15%+9.33%+18.49% 3.02B
-0.21%-6.36%+49.00%+74.13% 66.34B
-0.22%+10.10%+12.77%+87.32% 52.92B
+0.82%+9.46%+7.75%+73.53% 54.82B
+3.28%+6.12%+30.46%+50.05% 44.09B
+0.51%+10.71%+21.30%+133.92% 43.72B
-1.15%+3.10%+259.71%+594.60% 42.13B
+0.10%+9.96%+17.15%+59.33% 33.96B
-1.30%-3.61%+37.37%+7.16% 26.17B
+0.69%+6.07%+31.89%+26.94% 23.37B
Average -1.60%+4.00%+47.67%+112.55% 39.05B
Weighted average by Cap. +0.28%+3.73%+50.96%+126.92%

Financials

2026 *2027 *
Net sales 73.15M 65.18M 60.35M 54.61M 103M 6.9B 104M 724M 284M 3.63B 274M 269M 11.56B 56.52M 50.36M 46.63M 42.19M 79.5M 5.33B 80.44M 559M 219M 2.8B 212M 208M 8.93B
Net income -449M -400M -370M -335M -631M -42.36B -639M -4.44B -1.74B -22.27B -1.68B -1.65B -70.95B -413M -368M -341M -308M -581M -38.99B -588M -4.09B -1.6B -20.5B -1.55B -1.52B -65.31B
Net Debt -441M -393M -364M -329M -620M -41.58B -627M -4.36B -1.71B -21.86B -1.65B -1.62B -69.65B -102M -91.03M -84.28M -76.27M -144M -9.64B -145M -1.01B -397M -5.07B -383M -375M -16.15B
Projected Income Statement - Annual - Arcus Biosciences, Inc.
Logo Arcus Biosciences, Inc.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Employees
601
Date Price Change Volume
21/10/26 US$19.10 -19.58% 4,530,001
20/10/26 US$23.75 +7.27% 6,242,268
19/10/26 US$22.14 +0.09% 3,516,696
16/10/26 US$22.12 -3.07% 1,425,533
15/10/26 US$22.82 +1.29% 1,210,181
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Arcus Biosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
23.75USD
Average target price
41.69USD
Spread / Average Target
+75.55%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Arcus Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. RCUS Stock